Heath Skinner, MD, PhD, discussed which new radiation oncology service lines community practices can implement, how leadership decides, and what launches require.

“What we are trying to do more often is to ablate as much as we can,” said Shankar Siva, MBBS, PhD, FRANZCR, on pairing SABR with systemic therapy in RCC.

In the TOP-1 trial, omitting RT and endocrine therapy after breast-conserving surgery yielded a 14.8% 5-year local recurrence risk in women aged 70 and older.

Mingjia Li, MD, discussed the limitations of current biomarkers in selecting patients with resectable NSCLC for neoadjuvant chemoimmunotherapy.

Jan Kitajewski, PhD, discusses how an ancestry-linked blood type may influence triple-negative breast cancer outcomes and clinical trial eligibility.

A bispecific in biliary tract cancer, dostarlimab organ preservation in rectal cancer, and KRAS G12D data in pancreatic cancer stood out at ESMO 2026.

Dirk Schadendorf, MD, reviewed final STARBOARD data for encorafenib, binimetinib, and pembrolizumab in first-line BRAF V600–mutant melanoma.

Presentations at ESMO Congress 2026 detailed how surgery, radiation oncology, and supportive care can contribute to the treatment of patients with NSCLC.